Patients With BTC Eligible for First-Line Chemoimmunotherapy

During a Targeted Oncology case-based roundtable event, Nilofer S. Azad, MD, discussed the data supporting the previous standard of care and the new frontline regimen of gemcitabine, cisplatin, and durvalumab for patients with biliary tract cancers.

Milind Javle, MD, discusses the use of durvalumab for locally advanced or metastatic biliary tract cancer.